|
1
|
Buczek M, Escudier B, Bartnik E, Szczylik
C and Czarnecka A: Resistance to tyrosine kinase inhibitors in
clear cell renal cell carcinoma: From the patient's bed to
molecular mechanisms. Biochim Biophys Acta. 1845:31–41. 2014.
|
|
2
|
Młot B, Szczylik C and Rzepecki P: Seeking
new prognostic and predictive factors in patients with metastatic
renal cell carcinoma - hypoxia-induced factors. Contemp Oncol
(Pozn). 16:250–253. 2012.
|
|
3
|
Bielecka ZF, Czarnecka AM and Szczylik C:
Genomic analysis as the first step toward personalized treatment in
renal cell carcinoma. Front Oncol. 4:1942014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Porta C, Bellmunt J, Eisen T, Szczylik C
and Mulders P: Treating the individual: The need for a
patient-focused approach to the management of renal cell carcinoma.
Cancer Treat Rev. 36:16–23. 2010. View Article : Google Scholar
|
|
5
|
Escudier B, Szczylik C, Porta C and Gore
M: Treatment selection in metastatic renal cell carcinoma: Expert
consensus. Nat Rev Clin Oncol. 9:327–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ning X, Shu J, Du Y, Ben Q and Li Z:
Therapeutic strategies targeting cancer stem cells. Cancer Biol
Ther. 14:295–303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chow EK: Implication of cancer stem cells
in cancer drug development and drug delivery. J Lab Autom. 18:6–11.
2013. View Article : Google Scholar
|
|
8
|
Matak D, Szymanski L, Szczylik C,
Sledziewski R, Lian F, Bartnik E, Sobocinska A and Czarnecka AM:
Biology of renal tumour cancer stem cells applied in medicine.
Contemp Oncol (Pozn). 19:A44–A51. 2015.
|
|
9
|
Czarnecka AM and Szczylik C: Renal cell
carcinoma cancer stem cells as therapeutic targets. Curr Signal
Transduct Ther. 8:203–209. 2013. View Article : Google Scholar
|
|
10
|
Roskoski R Jr: Sunitinib: A VEGF and PDGF
receptor protein kinase and angiogenesis inhibitor. Biochem Biophys
Res Commun. 356:323–328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang D, Ding Y, Li Y, Luo WM, Zhang ZF,
Snider J, Vandenbeldt K, Qian CN and Teh BT: Sunitinib acts
primarily on tumor endothelium rather than tumor cells to inhibit
the growth of renal cell carcinoma. Cancer Res. 70:1053–1062. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Padhye SS, Guin S, Yao HP, Zhou YQ, Zhang
R and Wang MH: Sustained expression of the RON receptor tyrosine
kinase by pancreatic cancer stem cells as a potential targeting
moiety for antibody-directed chemotherapeutics. Mol Pharm.
8:2310–2319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Diaz R, Nguewa PA, Redrado M, Manrique I
and Calvo A: Sunitinib reduces tumor hypoxia and angiogenesis, and
radiosensitizes prostate cancer stem-like cells. Prostate.
75:1137–1149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Varna M, Gapihan G, Feugeas JP, Ratajczak
P, Tan S, Ferreira I, Leboeuf C, Setterblad N, Duval A, Verine J,
et al: Stem cells increase in numbers in perinecrotic areas in
human renal cancer. Clin Cancer Res. 21:916–924. 2015. View Article : Google Scholar
|
|
15
|
Adnane L, Trail PA, Taylor I and Wilhelm
SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that
targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases
VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407:597–612.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xin HW, Ambe CM, Hari DM, Wiegand GW,
Miller TC, Chen JQ, Anderson AJ, Ray S, Mullinax JE, Koizumi T, et
al: Label-retaining liver cancer cells are relatively resistant to
sorafenib. Gut. 62:1777–1786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chow AK, Ng L, Lam CS, Wong SK, Wan TM,
Cheng NS, Yau TC, Poon RT and Pang RW: The enhanced metastatic
potential of hepatocellular carcinoma (HCC) cells with sorafenib
resistance. PLoS One. 8:e786752013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hashimoto N, Tsunedomi R, Yoshimura K,
Watanabe Y, Hazama S and Oka M: Cancer stem-like sphere cells
induced from de-differentiated hepatocellular carcinoma-derived
cell lines possess the resistance to anti-cancer drugs. BMC Cancer.
14:7222014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamada T, Abei M, Danjoh I, Shirota R,
Yamashita T, Hyodo I and Nakamura Y: Identification of a unique
hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells
hierarchy and population change upon its differentiation during
culture and effects of sorafenib. BMC Cancer. 15:2602015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shan J, Shen J, Liu L, Xia F, Xu C, Duan
G, Xu Y, Ma Q, Yang Z, Zhang Q, et al: Nanog regulates self-renewal
of cancer stem cells through the insulin-like growth factor pathway
in human hepatocellular carcinoma. Hepatology. 56:1004–1014. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Galuppo R, Maynard E, Shah M, Daily MF,
Chen C, Spear BT and Gedaly R: Synergistic inhibition of HCC and
liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and
WNT/β-catenin pathways. Anticancer Res. 34:1709–1713.
2014.PubMed/NCBI
|
|
22
|
Gedaly R, Galuppo R, Musgrave Y, Angulo P,
Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, et al:
PKI-587 and sorafenib alone and in combination on inhibition of
liver cancer stem cell proliferation. J Surg Res. 185:225–230.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rausch V, Liu L, Kallifatidis G, Baumann
B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller
M, et al: Synergistic activity of sorafenib and sulforaphane
abolishes pancreatic cancer stem cell characteristics. Cancer Res.
70:5004–5013. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee JH, Shim JW, Choi YJ, Heo K and Yang
K: The combination of sorafenib and radiation preferentially
inhibits breast cancer stem cells by suppressing HIF-1α expression.
Oncol Rep. 29:917–924. 2013.PubMed/NCBI
|
|
25
|
Carra E, Barbieri F, Marubbi D, Pattarozzi
A, Favoni RE, Florio T and Daga A: Sorafenib selectively depletes
human glioblastoma tumor-initiating cells from primary cultures.
Cell Cycle. 12:491–500. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aldea MD, Petrushev B, Soritau O,
Tomuleasa CI, Berindan-Neagoe I, Filip AG, Chereches G, Cenariu M,
Craciun L, Tatomir C, et al: Metformin plus sorafenib highly
impacts temozolomide resistant glioblastoma stem-like cells. J
BUON. 19:502–511. 2014.PubMed/NCBI
|
|
27
|
Chen G, Nicula D, Renko K and Derwahl M:
Synergistic anti-proliferative effect of metformin and sorafenib on
growth of anaplastic thyroid cancer cells and their stem cells.
Oncol Rep. 33:1994–2000. 2015.PubMed/NCBI
|
|
28
|
Zhang K and Waxman DJ: Impact of tumor
vascularity on responsiveness to antiangiogenesis in a prostate
cancer stem cell-derived tumor model. Mol Cancer Ther. 12:787–798.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin
ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu
EY, et al: Nonclinical antiangiogenesis and antitumor activities of
axitinib (AG-013736), an oral, potent, and selective inhibitor of
vascular endothelial growth factor receptor tyrosine kinases 1, 2,
3. Clin Cancer Res. 14:7272–7283. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fenton BM and Paoni SF: The addition of
AG-013736 to fractionated radiation improves tumor response without
functionally normalizing the tumor vasculature. Cancer Res.
67:9921–9928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang F, Mi YJ, Chen XG, Wu XP, Liu Z, Chen
SP, Liang YJ, Cheng C, To KK and Fu LW: Axitinib targeted cancer
stemlike cells to enhance efficacy of chemotherapeutic drugs via
inhibiting the drug transport function of ABCG2. Mol Med.
18:887–898. 2012.PubMed/NCBI
|
|
32
|
Lu L, Saha D, Martuza RL, Rabkin SD and
Wakimoto H: Single agent efficacy of the VEGFR kinase inhibitor
axitinib in preclinical models of glioblastoma. J Neurooncol.
121:91–100. 2015. View Article : Google Scholar
|
|
33
|
McKenzie BA, Zemp FJ, Pisklakova A,
Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU and Forsyth
PA: In vitro screen of a small molecule inhibitor drug library
identifies multiple compounds that synergize with oncolytic myxoma
virus against human brain tumor-initiating cells. Neuro Oncol.
17:1086–1094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gomez-Casal R, Bhattacharya C, Ganesh N,
Bailey L, Basse P, Gibson M, Epperly M and Levina V: Non-small cell
lung cancer cells survived ionizing radiation treatment display
cancer stem cell and epithelial-mesenchymal transition phenotypes.
Mol Cancer. 12:942013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Conley SJ, Gheordunescu E, Kakarala P,
Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS:
Antiangiogenic agents increase breast cancer stem cells via the
generation of tumor hypoxia. Proc Natl Acad Sci USA. 109:2784–2789.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Piao Y, Liang J, Holmes L, Zurita AJ,
Henry V, Heymach JV and de Groot JF: Glioblastoma resistance to
anti-VEGF therapy is associated with myeloid cell infiltration,
stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol.
14:1379–1392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chinchar E, Makey KL, Gibson J, Chen F,
Cole SA, Megason GC, Vijayakumar S, Miele L and Gu JW: Sunitinib
significantly suppresses the proliferation, migration, apoptosis
resistance, tumor angiogenesis and growth of triple-negative breast
cancers but increases breast cancer stem cells. Vasc Cell.
6:122014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Clery JP, Gomez E, Sharma M, Khemani A,
Sharma C, Punzalan R, Navel M, Amezcua N, Jani J and Sharma J:
Optimal drug concentration screening and evaluation in cancer stem
cells & 3D tumor stem cell cultures drug response assays in
association with clinical efficacy for pancreatic cancer stem cell.
Cancer Res. 73:55452013. View Article : Google Scholar
|
|
39
|
Sharma J, DiMaggio CM, Taw N, Majdoub M,
Liles N, Velazquez G, Amezcua N, Sharma C and Sharma M: Human liver
cancer stem cells as a potential target for novel drug therapy and
drug discovery. The American Society for Cell Biology 2009 Annual
Meeting Regular; Abstracts, no. B48. 2009
|
|
40
|
Cleary JP, Raman D, Punzalan RR, et al:
Targeting cancer stem cells as potential new therapy for pancreatic
cancer. Cancer Res. 72:44082012. View Article : Google Scholar
|
|
41
|
Sharma CVR, Passarini JD, Majdoub MW,
DiMaggio CM, Sobhy OM, Punzalan RR, Sharma MRV, Harris-White ME,
Warden MW, Sharma SP and Sharma JP: Human triple-negative breast
cancer stem cells utilized for drug discovery therapeutics for
triple-negative breast cancer patients. Cancer Res. 70:33192010.
View Article : Google Scholar
|
|
42
|
Passarini J, Cleary JP, Kumar P, Newton T,
Sharma M, Sharma C, Panunzalan RR, Gill P, Sharma S, Srivastava R,
Shankar S and Sharma JP: Screening potential drug candidates for
treatment of glioblastoma patients utilizing an in-vivo mouse/rat
model system. Cancer Res. 71:33062011. View Article : Google Scholar
|
|
43
|
Ebert T, Bander NH, Finstad CL, Ramsawak
RD and Old LJ: Establishment and characterization of human renal
cancer and normal kidney cell lines. Cancer Res. 50:5531–5536.
1990.PubMed/NCBI
|
|
44
|
Breslin S and O'Driscoll L: Receptor
tyrosine kinase targeting in multicellular spheroids. Methods Mol
Biol. 1233:161–168. 2015. View Article : Google Scholar
|
|
45
|
Foty R: A simple hanging drop cell culture
protocol for generation of 3D spheroids. J Vis Exp.
51:27202011.PubMed/NCBI
|
|
46
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH Image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Abramoff MD, Magalhaes PJ and Ram SJ:
Image processing with ImageJ. Biophotonics Int. 11:36–42. 2004.
|
|
48
|
Nakayama GR, Caton MC, Nova MP and
Parandoosh Z: Assessment of the Alamar Blue assay for cellular
growth and viability in vitro. J Immunol Methods. 204:205–208.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Triglia D, Sherard Braa S, Yonan C and
Naughton GK: Cytotoxicity testing using neutral red and MTT assays
on a three-dimensional human skin substrate. Toxicol In Vitro.
5:573–578. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vistica DT, Skehan P, Scudiero D, Monks A,
Pittman A and Boyd MR: Tetrazolium-based assays for cellular
viability: A critical examination of selected parameters affecting
formazan production. Cancer Res. 51:2515–2520. 1991.PubMed/NCBI
|
|
51
|
Machesky LM: Lamellipodia and filopodia in
metastasis and invasion. FEBS Lett. 582:2102–2111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Négrier S and Raymond E: Antiangiogenic
treatments and mechanisms of action in renal cell carcinoma. Invest
New Drugs. 30:1791–1801. 2012. View Article : Google Scholar
|
|
53
|
O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ,
Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, et al: SU11248
is a novel FLT3 tyrosine kinase inhibitor with potent activity in
vitro and in vivo. Blood. 101:3597–3605. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wiernik PH: FLT3 inhibitors for the
treatment of acute myeloid leukemia. Clin Adv Hematol Oncol.
8:429–436. 4442010.PubMed/NCBI
|
|
55
|
Karaman MW, Herrgard S, Treiber DK,
Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI,
Edeen PT, et al: A quantitative analysis of kinase inhibitor
selectivity. Nat Biotechnol. 26:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kitagawa D, Yokota K, Gouda M, Narumi Y,
Ohmoto H, Nishiwaki E, Akita K and Kirii Y: Activity-based kinase
profiling of approved tyrosine kinase inhibitors. Genes Cells.
18:110–122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mendel DB, Laird AD, Xin X, Louie SG,
Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et
al: In vivo antitumor activity of SU11248, a novel tyrosine kinase
inhibitor targeting vascular endothelial growth factor and
platelet-derived growth factor receptors: Determination of a
pharmacokinetic/pharmaco-dynamic relationship. Clin Cancer Res.
9:327–337. 2003.PubMed/NCBI
|
|
58
|
Potapova O, Laird AD, Nannini MA, Barone
A, Li G, Moss KG, Cherrington JM and Mendel DB: Contribution of
individual targets to the antitumor efficacy of the multitargeted
receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther.
5:1280–1289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gotink KJ, Broxterman HJ, Labots M, de
Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters
RJ, Jansen G, et al: Lysosomal sequestration of sunitinib: A novel
mechanism of drug resistance. Clin Cancer Res. 17:7337–7346. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gotink KJ, Broxterman HJ, Honeywell RJ,
Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters
GJ, Pili R, et al: Acquired tumor cell resistance to sunitinib
causes resistance in a HT-29 human colon cancer xenograft mouse
model without affecting sunitinib biodistribution or the tumor
microvasculature. Oncoscience. 1:844–853. 2014. View Article : Google Scholar
|
|
61
|
Ma J, Chen CS, Blute T and Waxman DJ:
Antiangiogenesis enhances intratumoral drug retention. Cancer Res.
71:2675–2685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Al Hazzouri A, Vaziri SA, Lynch M,
Schwartz B, Rini BI, Bukowski R and Ganapathy R: Anti-proliferative
effects of sorafenib in clear cell renal cell carcinoma (CCRCC)
cell lines: Relationship to von Hippel-Lindau protein (pVHL)
expression and hypoxia. J Clin Oncol. 24:46012006.
|
|
63
|
Juengel E, Kim D, Makarević J, Reiter M,
Tsaur I, Bartsch G, Haferkamp A and Blaheta RA: Molecular analysis
of sunitinib resistant renal cell carcinoma cells after sequential
treatment with RAD001 (everolimus) or sorafenib. J Cell Mol Med.
19:430–441. 2015. View Article : Google Scholar :
|
